SMD
Standard mean difference
Standard mean difference
(SMD) was used in meta-analysis using random effect model.
We evaluated treatment effects for continuous and dichotomous outcomes using
standardised mean difference
(SMD) and risk ratios (RR), respectively, employing random-effects meta-analyses.
Brain injury outcomes were extracted for meta-analysis to calculate
standard mean difference
(SMD) with 95% confidence interval (CI), using an inverse variance, random effects model.
Non-significant
standardised mean differences
(SMD) were found for depression symptoms (SMD = - 0.17, 95% CI [- 0.41, 0.07], p = 0.16) and diabetes-related distress (SMD = - 0.12, 95% CI [- 0.27, 0.04], p = 0.13).
The pooled results indicated that PMR interventions improved the sleep quality score
standardized mean difference
(SMD): -0.23; 95% confidence interval (CI): -0.54, 0.07; P = .13, level of anxiety SMD: -1.35; 95% CI -2.38, -0.32; P = .01 compared to the usual care.
We compared healthy and pathologic PF stiffness using the
standardised mean difference
(SMD) in a random-effects model (95% CI).
Standardized mean differences
(SMDs) of tau tracer uptake were calculated using random-effects models.
Our meta-analysis showed that the administration of TXA is associated with decreased total blood loss of
standardized mean difference
(SMD) of -1.40 (95% CI [-2.49, -0.31]), anesthetic time SMD -0.36 (95% CI [-0.63, -0.09]), and blood transfusion requirements RR 0.58 (95% CI [0.34, 0.99]).
Standardized mean difference
(SMD) with 95% confidence interval (CI) in circulating copper level between liver cancer patients and controls were pooled.
The
standardised mean difference
(SMD) with a 95% confidence interval (CI) was calculated.